all report title image
  • Published On : Nov 2021
  • Code : CMI4794
  • Industry : Pharmaceutical
  • Pages : 156
  • Formats :

Basal cell carcinoma (BCC) is uncontrolled and abnormal growth is seen in the basal cells of the lower epidermis. It does not spread to other body parts but in the rare condition it may metastasize and can be proved as life-threatening; however, it may go deep in skin and bones. It is caused due to the overexposure to ultraviolet rays and the lesions formed during the BCC looks like open sores, red patches, or sometimes look like bumps. There are various treatment options available for the treatment of basal cell carcinoma which includes surgery, drugs, and others

The global basal cell carcinoma market is estimated to be valued at US$ 6,721.4 million in 2021 and is expected to exhibit a CAGR of 7.9% during the forecast period (2021-2028).

Figure 1. Global Basal Cell Carcinoma Market Share (%) in Terms of Value, by Treatment Type, 2021

Basal Cell Carcinoma  | Coherent Market Insights

Increasing prevalence of skin malignancies is expected to drive the market growth during the forecast period.

The increasing prevalence of skin malignancies is expected to drive the global basal cell carcinoma market growth over the forecast period. For instance, according data published in The Skin Cancer Foundation in 2021, estimated that Basal cell carcinoma (BCC) is the most common form of skin cancer. Moreover, an estimated 3.6 million cases of BCC are diagnosed in the U.S. each year.

CMI table icon

Basal Cell Carcinoma Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 6,721.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 7.9% 2028 Value Projection: US$ 11,458.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, Sou th Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type: Surgical (Surgical Excision, Electrodessication & Cutterage ED&C, Moh's Surgery, Cryosurgery), Drugs (Topical Treatment, Advanced Medication, Other), Others (Radiation Therapy, Photodynamic Therapy PDT, Laser Therapy)
  • By End User: Hospitals, Specialty Clinics, Others
Companies covered:

Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Perrigo Company plc, Taro Pharmaceutical Industries Ltd., Provectus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Mylan N.V.

Growth Drivers:
  • Increased prevalence of  skin malignancies
  • Product approval for the treatment of  basal cell carcinoma
Restraints & Challenges:
  • High costs for basal cell carcinoma treatment
  • Delay in accessing medical conditions
  • After effects of the treatment and approval time for the drugs taking too long

Figure 2. Global Basal Cell Carcinoma Market Share (%), by End User, 2021

Basal Cell Carcinoma  | Coherent Market Insights

Product approval for the treatment of basal cell carcinoma are expected to drive the market growth during the forecast period.

Key players operating in the market are focusing on product approvals for the treatment of basal cell carcinoma, which is expected to drive the global basal cell carcinoma market growth during the forecast period. For instance, in June 2021, Sanofi, a French multinational pharmaceutical corporation headquartered in Paris, France, announced that the European Commission (EC) had approved Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).

Global Basal Cell Carcinoma Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 256 million infected individuals worldwide as of November 22, 2021.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the global basal cell carcinoma market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.

Global Basal Cell Carcinoma Market: Restraint

The major factors that hinder the growth of the global basal cell carcinoma market include high costs for basal cell carcinoma treatment, after effects of the treatment, approval time for the drugs taking too long, and delay in accessing medical conditions. There is often a delay between the clinical emergence of a basal cell carcinoma (BCC) and the point in time at which the patient presents for definitive diagnosis and treatment. This acts as a restraint and can cause lesser demand in treatments owing to late diagnosis.

Key Players

Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Perrigo Company plc, Taro Pharmaceutical Industries Ltd.,  Provectus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Mylan N.V.

Basal cell carcinoma is a type of skin cancer. Basal cell carcinoma begins in the basal cells a type of cell within the skin that produces new skin cells as old ones die off. Basal cell carcinoma often appears as a slightly transparent bump on the skin, though it can take other forms. Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as head and neck.  It is more common among fair-skinned people with sun exposure and is very rare among dark-skinned people.

Market Dynamics

Key players operating in the global basal cell carcinoma market are focusing on adoption of growth strategies such as product launch, regulatory approval, and research and development for the treatment of basal cell carcinoma, which is expected to drive the market growth during the forecast period. For instance, in January 2021, Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced dose administration for the first patient in a phase 2a clinical study of the company's lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma. Moreover, in November 18 2021, Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that the U.S. Food and Drug Administration had accepted the company’s investigational new drug application for LTX-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. The company expects to initiate its phase II trial of LTX-315 in basal cell carcinoma in the first quarter of 2022.

Key features of the study:

  • This report provides in-depth analysis of the global basal cell carcinoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global basal cell carcinoma market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Perrigo Company plc, Taro Pharmaceutical Industries Ltd., Provectus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Mylan N.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global basal cell carcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global basal cell carcinoma market

Detailed Segmentation:

  • Global Basal Cell Carcinoma Market, By Treatment Type :
    • Surgical
      • Surgical Excision
      • Electrodessication & Cutterage ED&C
      • Moh's Surgery
      • Cryosurgery
    • Drugs
      • Topical Treatment
      • Advanced Medication
      • Other
    • Others
      • Radiation Therapy
      • Photodynamic Therapy PDT
      • Laser Therapy
  • Global Basal Cell Carcinoma Market, By End User :
      • Hospitals
      • Specialty Clinics
      • Others
  • Global Basal Cell Carcinoma Market, By Region:
    • North America
      • By Treatment Type
        • Surgical
          • Surgical Excision
          • Electrodessication & Cutterage ED&C
          • Moh's Surgery
          • Cryosurgery
        • Drugs
          • Topical Treatment
          • Advanced Medication
          • Other
        • Others
          • Radiation Therapy
          • Photodynamic Therapy PDT
          • Laser Therapy
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Treatment Type
        • Surgical
          • Surgical Excision
          • Electrodessication & Cutterage ED&C
          • Moh's Surgery
          • Cryosurgery
        • Drugs
          • Topical Treatment
          • Advanced Medication
          • Other
        • Others
          • Radiation Therapy
          • Photodynamic Therapy PDT
          • Laser Therapy
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Treatment Type
        • Surgical
          • Surgical Excision
          • Electrodessication & Cutterage ED&C
          • Moh's Surgery
          • Cryosurgery
        • Drugs
          • Topical Treatment
          • Advanced Medication
          • Other
        • Others
          • Radiation Therapy
          • Photodynamic Therapy PDT
          • Laser Therapy
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment Type
        • Surgical
          • Surgical Excision
          • Electrodessication & Cutterage ED&C
          • Moh's Surgery
          • Cryosurgery
        • Drugs
          • Topical Treatment
          • Advanced Medication
          • Other
        • Others
          • Radiation Therapy
          • Photodynamic Therapy PDT
          • Laser Therapy
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment Type
        • Surgical
          • Surgical Excision
          • Electrodessication & Cutterage ED&C
          • Moh's Surgery
          • Cryosurgery
        • Drugs
          • Topical Treatment
          • Advanced Medication
          • Other
        • Others
          • Radiation Therapy
          • Photodynamic Therapy PDT
          • Laser Therapy
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment Type
        • Surgical
          • Surgical Excision
          • Electrodessication & Cutterage ED&C
          • Moh's Surgery
          • Cryosurgery
        • Drugs
          • Topical Treatment
          • Advanced Medication
          • Other
        • Others
          • Radiation Therapy
          • Photodynamic Therapy PDT
          • Laser Therapy
      • By End User
        • Hospitals
        • Specialty Clinics
        • Others
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Merck & Co., Inc.,*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Sun Pharmaceutical Industries Ltd
    • Novartis AG
    • Bausch & Lomb Incorporated.
    • Allergan
    • Perrigo Company plc
    • Taro Pharmaceutical Industries Ltd
    • Provectus Biopharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Mylan N.V.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global basal cell carcinoma market size is estimated to be valued at US$ 6,721.4 million in 2021 and is expected to exhibit a CAGR of 7.9% between 2021 and 2028.
Factors such as increased prevalence of skin malignancies, and product approval for the treatment of basal cell carcinoma are driving the market growth.
Surgical segment is expected to hold a major market share during the forecast period.
The major factors hampering growth of the market include high costs for basal cell carcinoma treatment, after effects of the treatment, approval time for the drugs taking too long, and delay in accessing medical conditions.
Major players operating in the market include Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Perrigo Company plc, Taro Pharmaceutical Industries Ltd., Provectus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Mylan N.V.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo